Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
APOLLOHOSPNSEApollo Hospitals Enterprise Limited· Healthcare ServicesHighPositive
Announced Fri, 12 Sept, 2025 · 19:11 IST

Apollo to acquire IFC stake in AHLL and expand Gurugram oncology

Listed Co AcquisitionStrategic Transactions View source PDFExplain this filing

APOLLOHOSP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.5%Reaction day
₹7864.50
prior close
₹7900.00
announcement price
After-mkt
timing
Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.0%-0.5% vs market
Hospital peers, median of 18sector+0.5%-1.0% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty 100 and 1.0 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.6
10m
-0.5
15m
-0.8
30m
-1.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.5-0.0-0.5+0.5-1.0
Next day
-0.0+0.6-0.7+0.5-0.5
2d
+0.1+1.0-0.9+0.2-0.1
3d
-0.3+1.3-1.6+0.1-0.4
4d
-0.8+1.1-1.8-1.3+0.5
5d
-1.5+0.7-2.3-0.8-0.7
1w
-2.6-0.0-2.5-2.2-0.4
15d
-2.1+0.1-2.2+0.8-2.9
1m
-0.6+0.9-1.6+0.8-1.4
2m
-4.8+3.5-8.3-1.3-3.5
3m
-9.8+3.1-12.9-5.8-3.9
UpDownMarket · Nifty 100Sector · Hospital peers, median of 18Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

On September 12, 2025, Apollo approved buying 41,650,368 AHLL shares, or 30.58%, from IFC and IFC EAF for Rs 12,540.68 million at Rs 301.09 per share. The deal needs Competition Commission approval and is expected to close by end-November 2025, lifting AHLL ownership to 99.42%. Apollo also approved a Rs 5,730 million, 100-bed Gurugram oncology centre with a Proteus One proton system, targeted for completion by FY2029.

Likely market impact

Fuller control of AHLL may improve integration and returns, while oncology expansion supports growth. Cash outlay and execution risks remain.